To conclusively validate that the antibody was indeed recognizing the endogenous PANK3 protein, we employed the CRISPR–Cas9 technology to knock out PANK3 protein in two different cancer cell lines—HAP1 and HeLa (Figure 5B,C, Supplemental Figure S6). Here, PANK3 is linked to cancer.